BTAI - CIK 0001720893
BioXcel Therapeutics, Inc. trades as BTAI. In its fiscal 2025 annual report the company posted revenue of $642.00K, down 71.7% from the prior year and net income of -$69.90M. This page tracks BioXcel Therapeutics, Inc. through 656 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -44201.9% to -10887.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
The largest companies sharing BioXcel Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
BioXcel Therapeutics, Inc. reported revenue of $642.00K for fiscal year 2025, a decrease of 71.7% year over year.
In its latest fiscal year BioXcel Therapeutics, Inc. reported a net loss of $69.90M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.